Key Findings From Recent Trials

Basic Casodex Information

• INN (International Nonproprietary Name): Bicalutamide
• Brand Names Available In United Kingdom: Casodex — 50 mg film‑coated tablets (AstraZeneca)
• ATC Code: L02BB03
• Forms & Dosages: Tablets 50 mg and 150 mg; blisters typically 28, 30, 60 or 100 units; global availability, prescription only
• Manufacturers In United Kingdom: Originator AstraZeneca; generics available from multiple suppliers globally (Cipla, Intas, R‑Pharm listed)
• Registration Status In United Kingdom: Casodex 50 mg film‑coated tablets marketed by AstraZeneca and prescription‑only; check local MHRA/NHS formularies for regional guidance
• OTC / Rx Classification: Prescription only (Rx)

Major 2022–2025 Studies

Recent phase II–III analyses emphasise bicalutamide’s continued role when combined with LHRH analogues for metastatic prostate cancer.

Head‑to‑head comparisons versus newer agents such as enzalutamide and apalutamide focused on progression‑free survival and quality‑of‑life trade‑offs.

Large real‑world cohorts from 2019–2024 show persistent use of Casodex 50 mg daily alongside LHRH analogues in older patients because of tolerability and cost advantages.

Reports across UK practice highlight that clinicians still choose bicalutamide for anti‑androgen cover at the time of LHRH agonist initiation in many cases.

Main Outcomes

Progression‑free survival gains over LHRH analogue alone were generally modest in the analysed trials.

Overall survival benefits were variable and often appeared influenced by patient selection and baseline disease characteristics.

Multiple analyses consistently reported reduced central nervous system adverse events compared with second‑generation androgen receptor inhibitors.

Safety Observations

Hepatic enzyme elevations and gynaecomastia remain the most commonly signalled adverse effects in the trial and cohort data.

Serious hepatic events are rare but present, supporting routine monitoring protocols in the early months of therapy.

Use of Casodex (bicalutamide) 50 mg film‑coated tablets from AstraZeneca remains standard in combination regimens in the UK.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask how casodex works and why it is used with injections that lower testosterone.

Bicalutamide is an oral anti‑androgen that binds to androgen receptors in prostate cells and blocks testosterone and dihydrotestosterone from stimulating tumour growth.

Given alongside LHRH analogues, it prevents the transient testosterone stimulation known as a flare and reduces overall androgen signalling to the tumour.

Scientific Breakdown

Bicalutamide (INN: bicalutamide; ATC L02BB03) is a non‑steroidal pure antagonist at the androgen receptor.

The drug competitively inhibits AR nuclear translocation and AR‑DNA binding, lowering transcription of androgen‑responsive genes.

Typical pharmacokinetics support once‑daily dosing with 50 mg commonly used in combination regimens and 150 mg in some monotherapy protocols.

Hepatic metabolism is the main elimination route and so caution is advised in patients with liver impairment.

Molecular Notes

Metabolites of bicalutamide retain low AR affinity and the long half‑life supports once‑daily dosing.

Casodex is marketed as 50 mg and 150 mg film‑coated tablets, with AstraZeneca named as the originator.

Scope Of Approved & Off-Label Use

United Kingdom Approvals

Casodex is available in the UK as 50 mg film‑coated tablets from AstraZeneca and is prescription‑only.

Labelled indications historically include metastatic prostate cancer in combination with LHRH analogues and locally advanced disease.

Some national formularies note region‑specific monotherapy use at 150 mg for locally advanced non‑metastatic disease; local NHS or MHRA guidance should be confirmed before prescribing.

Notable Off‑Label Trends

Short‑term anti‑androgen cover to prevent testosterone flare when starting LHRH agonists is a common off‑label practical use.

Occasional use occurs for patients who cannot tolerate newer AR inhibitors, often driven by tolerability or cost considerations.

Real‑world prescribing in the UK commonly favours 50 mg daily combined therapy due to a balance of tolerability and affordability.

Dosage Strategy

General Dosing

Standard adult dosing in the UK is 50 mg once daily when used in combination with an LHRH analogue.

Certain locally advanced non‑metastatic patients may be given 150 mg once daily as monotherapy where allowed by regional protocols; always verify local guidance.

Condition‑Specific Dosing

For metastatic disease, bicalutamide 50 mg is continued alongside LHRH analogue indefinitely until progression or intolerable toxicity.

In selected locally advanced cases, 150 mg once daily monotherapy is sometimes used for defined treatment periods commonly of two years or more according to protocol.

There is no paediatric indication and the medicine is contraindicated in children and women.

Special Populations

Elderly patients typically require no routine dose adjustment and standard doses are usually appropriate.

Renal impairment rarely requires dose change, but moderate‑to‑severe hepatic impairment is not recommended and needs careful assessment.

Casodex is distributed in tablet strengths of 50 mg and 150 mg in blister packs, prescription only.

Safety Protocols

Contraindications

Absolute contraindications include women and children, known hypersensitivity to bicalutamide or excipients, and severe hepatic impairment.

Mild‑to‑moderate hepatic disease and concomitant use of anticoagulants such as warfarin are relative contraindications that require caution and monitoring.

Adverse Effects

Common adverse effects are hot flashes, gynaecomastia or breast tenderness, rash, fatigue and peripheral oedema.

Gastrointestinal symptoms such as nausea, diarrhoea or constipation are reported alongside anaemia and musculoskeletal pain.

Elevated liver enzymes (ALT/AST) are a known laboratory signal and should be checked before and during treatment.

Monitoring Schedule (Practical UK Approach)

Obtain baseline liver function tests prior to starting casodex and repeat LFTs at around one to three months after initiation.

Further monitoring should be guided by initial results and clinical signs; patients should be told to report jaundice, severe fatigue or unusual bruising promptly.

Store Casodex below 25°C and remind patients that the tablet is prescription only and must be kept in original packaging.

Interaction Mapping

Food Interactions

There are no major food‑effect contraindications listed in the primary product data.

Advise patients to take casodex consistently with regard to meals to maintain routine and adherence.

Keep the tablets in original packaging and protect them from moisture during storage.

Drug Combinations To Avoid

Bicalutamide can alter INR and so caution is required with warfarin and other drugs with a narrow therapeutic index.

Avoid combining casodex with other hepatotoxic medicines where possible and monitor liver enzymes closely if co‑administration cannot be avoided.

When switching patients to second‑generation AR inhibitors such as enzalutamide or apalutamide, pay attention to overlapping toxicities.

Practical Checks For Prescribers

Review hepatic enzyme trends and the patient’s full medication list for interactions that may affect metabolism or bleeding risk.

Use up‑to‑date drug interaction resources and coordinate closely with oncology pharmacists for complex treatment regimens.

Patient Experience Analysis

Survey Data

Practice audits and patient surveys show many patients on Casodex 50 mg tolerate treatment well with manageable side effects.

Quality‑of‑life measures in older, frailer populations often favour bicalutamide compared with agents associated with higher CNS effects.

Common patient concerns noted in surveys are hot flashes and breast changes rather than severe cognitive effects.

Forum Trends

UK and EU patient forums commonly mention gynaecomastia, transient fatigue and the convenience of a once‑daily oral tablet.

Discussion threads frequently emphasise the importance of liver enzyme checks and express worry about costs outside the NHS.

Practical Patient Advice

Clinicians should discuss likely side effects at the start, explain liver monitoring schedules and offer practical measures for gynaecomastia such as supportive garments or surgical referral if persistent.

Be clear about when to seek urgent review for symptoms suggestive of hepatic injury.

Distribution & Pricing Landscape

Casodex is an established branded product from AstraZeneca with global distribution and branded 50 mg film‑coated tablets commonly stocked in the UK.

Generics are available from manufacturers such as Cipla, Intas and R‑Pharm and these are frequently preferred by NHS procurement where clinically suitable.

Branded Casodex is typically priced higher than generic bicalutamide preparations, and supply dynamics sometimes drive regional prescribing choices.

Occasional regional generic shortages have affected availability in recent years, so pharmacies track supply closely and may substitute with licensed generics.

In our online pharmacy, casodex is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

The following comparison highlights alternative anti‑androgens and their practical considerations.

• Flutamide (Eulexin): older non‑steroidal anti‑androgen with hepatotoxic risk.
• Nilutamide (Nilandron): alternative anti‑androgen with unique adverse profile including visual disturbance in some cases.
• Enzalutamide (Xtandi): second‑generation AR inhibitor with higher potency but increased CNS side effects and cost.
• Apalutamide (Erleada): potent AR inhibitor used in specific indications with notable efficacy in certain settings but higher toxicity and expense.
• Bicalutamide (Casodex): well tolerated, lower CNS effects, cost‑effective but less potent for some endpoints compared with newer AR inhibitors.

Pros And Cons

Bicalutamide’s advantages are tolerability in older patients, ease of once‑daily oral dosing and lower incidence of cognitive adverse effects.

Newer agents such as enzalutamide and apalutamide generally offer greater efficacy in non‑metastatic castration‑resistant settings but bring higher rates of fatigue, falls and cognitive adverse events and greater cost.

Regulatory Status

Bicalutamide (INN) is authorised across many regions and Casodex is the AstraZeneca originator product.

The EMA authorised the medicine in 1995 and the FDA lists approvals for metastatic and locally advanced prostate cancer.

In the UK, Casodex 50 mg film‑coated tablets are marketed by AstraZeneca and are prescription‑only.

Prescribers and pharmacies should check MHRA and NHS formularies for any regional prescribing restrictions or licensing nuances before issuing treatment.

Routine pharmacovigilance reporting of hepatic events and serious adverse reactions is recommended via the Yellow Card scheme in the UK.

Consolidated FAQ

Q: Can Casodex be used with LHRH analogues?

A: Yes — the standard approach is 50 mg once daily with an LHRH analogue for metastatic prostate cancer.

Q: Is 150 mg used?

A: A 150 mg monotherapy regimen is used selectively for locally advanced disease in some regions; always confirm local guidance.

Q: What monitoring is needed?

A: Baseline and periodic liver function tests are recommended, especially in the first one to three months; report jaundice or severe malaise promptly.

Q: Can women take it?

A: No — bicalutamide is contraindicated in women.

Q: Any dose adjustments?

A: Elderly patients and those with renal impairment usually require no dose change; avoid use in moderate‑to‑severe hepatic impairment.

Visual Guide

Suggested visuals for UK audiences include a photograph of Casodex 50 mg film‑coated tablets in blister packaging and an infographic explaining androgen receptor blockade.

A treatment pathway flowchart showing initiation with LHRH plus Casodex and scheduled monitoring checkpoints helps patients understand the process.

Side‑effect incidence tables and management steps, with icons for “prescription only”, “store below 25°C”, and “report via Yellow Card”, aid comprehension.

Always label images with INN: bicalutamide and brand: Casodex, and show tablet strengths and typical blister sizes to assist identification.

Storage & Transport

Store Casodex below 25°C and protect it from light and moisture.

Keep tablets in original packaging until use and avoid placing them in bathrooms or humid places at home.

Transport should follow regulations for prescription medicines and maintain dry conditions to avoid temperature and humidity excursions.

Pharmacies should label dispensed packs with clear patient instructions and confirm batch and expiry details at dispensing.

Advise patients to keep the medicine out of reach of children and not to transfer tablets to unsealed containers that could expose them to humidity.

Delivery Across United Kingdom

Guidelines For Proper Use

Confirm the indication before prescribing, distinguishing metastatic disease from locally advanced non‑metastatic cases.

Choose dose according to indication: 50 mg daily with LHRH analogue or 150 mg daily monotherapy only where locally approved.

Obtain baseline LFTs and arrange an initial repeat around one to three months after starting treatment.

Counsel patients on expected side effects such as hot flashes and gynaecomastia and explain when to seek urgent review for hepatic symptoms.

Advise patients to take the tablet at the same time every day and not to double the next dose if they miss one.

Keep accurate prescription records, discuss potential interactions especially with warfarin, and report suspected serious adverse reactions via the Yellow Card scheme.

For private or export prescriptions, ensure correct brand or generic labelling and compliance with supply regulations and documentation.